| Date | Title | Description |
| 11.09.2026 | Key approvals, positive study results and a partnership deal to fast track new medications |
BioVersys, a multi-asset biotech company focused on the development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria, has been granted Fast Track designation by the U.S. ... |
| 19.06.2026 | Swiss biotechs display their innovations at BIO 2026 in San Diego |
The BIO International Convention attracts over 1,600 exhibitors and 21,000 attendees who network intensively over 4 days, discover new opportunities and promising partnerships. The attendees benefit from a broad spectrum of life sciences a... |
| 19.03.2026 | Swiss biotechs advance clinical programs across multiple therapeutic areas |
Pilatus Biosciences, a startup based in Vaud, is developing novel immunotherapies for liver and gastrointestinal cancers. Founded in 2022 from the Ludwig Institute for Cancer Research and supported by the Cancer Research Institute, Pilatus... |
| 17.02.2026 | From Ideas to IPO: The structured path behind Switzerland’s next listed companies | 17.02.2026 14:00, Markus Hammer
Switzerland’s strongest deeptech startups share more than scientific excellence. They share a development journey that systematically transforms early-stage innovation into globally competitive companies. Wha... |
| 04.02.2026 | Swiss Startups Defy Global Headwinds, Secure Billions in Landmark Funding Year | Swiss startups delivered a stunning performance in 2025. They defied a volatile global economy and sluggish growth. Venture capital funding surged to nearly CHF 3 billion across 354 rounds. This marked the first significant increase since 2... |
| 03.02.2026 | Significantly more money for Swiss start-ups |
The global political situation is unstable, economic growth is sluggish and export-oriented industries are suffering from uncertain prospects. The environment in 2025 was anything but favourable. Nevertheless, for the first time since 2022... |
| 03.02.2026 | Hausse massive des fonds pour les startups suisses |
La situation politique mondiale est instable, la croissance économique est faible et les secteurs exportateurs souffrent de perspectives incertaines. En 2025, le contexte était tout sauf favorable. Néanmoins, pour la première fois depuis 2... |
| 03.02.2026 | CHF 2.9 billion for Swiss startups in 2025 | 03.02.2026 09:29, Rita Longobardi
Investment in Swiss hightech startups rose by 23.9% to CHF 2.9 billion in 2025, according to Swiss Venture Capital Report, published by the online news portal startupticker.ch and the industry association S... |
| 03.02.2026 | Massiv mehr Geld für Schweizer Startups |
Die weltpolitische Lage ist instabil, die Wirtschaft wächst nur wenig und die exportierenden Branchen leiden unter unsicheren Aussichten. Das Umfeld war 2025 alles andere als günstig. Trotzdem floss erstmals seit 2022 wieder mehr Geld in S... |
| 11.12.2025 | Biotechs advance therapies against bacterial infections and peanut allergies |
BioVersys’ novel antibiotic candidate, BV100, an intravenous antibiotic candidate developed to treat severe hospital infections caused by Acinetobacter baumannii, has advanced into a global registration Phase 3 study program in drug-resist... |
| 12.11.2025 | Superbug Fight Escalates: BioVersys Secures Major Funding for Novel Antibiotic Trial | BioVersys receives CHF 14 million from Wellcome for a pivotal BV100 Phase 2b clinical trial. This study tackles carbapenem-resistant Acinetobacter baumannii (CRAB), a "critical" WHO priority pathogen. BV100 offers a novel intraven... |
| 11.11.2025 | BioVersys secures CHF 14 million for new clinical study on hospital infections | BV100 is a novel intravenous formulation of rifabutin developed to treat hospital-acquired infections caused by Acinetobacter baumannii, including carbapenem-resistant strains (CRAB). The compound features a newly identified mechanism of ac... |
| 10.11.2025 | Wellcome awards CHF 14 million for BioVersys’ BV100 Phase 2b study |
As a lead candidate in BioVersys’ portfolio, BV100 is a novel formulation of rifabutin suitable for intravenous administration, with a recently discovered novel mode of action showing an active uptake of rifabutin into the Gram-negative ba... |
| 07.11.2025 | Tech and biopharma startups expand executive teams |
Founded in Chavannes-de-Bogis,Vaud, in 2023, Snapbau is developing a digital platform that enables construction companies to manage their entire procurement and tendering processes centrally and efficiently, covering material and equipment... |
| 07.11.2025 | Development milestones and financing for biotech companies |
Timeline, a longevity biotech company behind Mitopure® (Urolithin A) — a postbiotic that stimulates mitophagy, the body’s cellular recycling process critical for mitochondrial and metabolic health — has published a new clinical study on im... |
| 31.10.2025 | More than 20 Swiss biotech companies to exhibit at Bio Europe |
Bio-Europe, the leading partnering conference for the global biotechnology industry, is held annually to connect biotech, pharma, investors, and service providers through one-to-one meetings, presentations, and panels. It serves as a leadi... |
| 02.09.2025 | Regulatory milestones and clinical progress for Swiss biotechs |
TOLREMO therapeutics AG, a Swiss biotech startup redefining cancer treatment by targeting non-oncogene addiction, has obtained two Fast Track designations from the U.S. Food and Drug Administration (FDA) for its lead candidate, TT125-802 f... |
| 02.07.2025 | BioVersys enters into research and license option agreement with Shionogi & Co |
The joint research teams of BioVersys and Shionogi & Co aim to deliver clinical candidates and back-up molecules during the research collaboration period. Shionogi will have the exclusive option to license a selected number of molecule... |
| 06.05.2025 | Private biotech companies set new records |
During 2024, Switzerland’s biotech sector continued to demonstrate resilience despite significant financial and market challenges. Revenues remained strong at CHF 7.2 billion, while R&D investment grew to CHF 2.6 billion. Private biote... |
| 19.03.2025 | Biotech updates: A first dosing and a setback | LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, launched the Phase 1 clinical trial (NCT06719219) in the U.S. after receiving a Fast Track designation from the U.... |
| 07.02.2025 | BioVersys Opens IPO Season at SIX Swiss Exchange |
With today’s successful Initial Public Offering (IPO), BioVersys marks a significant milestone in its journey from a Basel-based startup to a publicly traded company, reinforcing the positioning of SIX as Europe’s leading life sciences exc... |
| 29.01.2025 | Venture Kick alumni: job creation and investment strengthen Swiss economy |
The Venture Kick Annual Report 2024 highlights the continued success of the Kick Foundation initiative in solidifying Switzerland’s position as a global innovation leader. In 2024, Venture Kick experienced significant growth in startup app... |
| 29.01.2025 | BioVersys to go public next week |
BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multidrug-resistant (MDR) bacteria, announced toda... |
| 21.01.2025 | BioVersys to go public at SIX Swiss Exchange |
BioVersys’ two clinical programs address life-threatening antibiotic resistant bacterial infections, focusing on profitable indications within the antibiotic space, in pneumonia, blood stream infections and meningitis.
BioVersys’ two clini... |
| 08.11.2024 | Bio-Europe: Switzerland's Biotech Showcase in Stockholm | The heart of Europe beats strong in Stockholm this November. Bio-Europe, the continent's premier partnering event for the life sciences, is back for its 30th edition. This year, it promises to be a melting pot of innovation, collaboration, ... |
| 05.11.2024 | Bio Europe in Stockholm hosts 33 Swiss companies |
Currently in its 30-year-edition, BIO-Europe remains Europe's leading partnering event, for the life sciences ecosystem, providing an exceptional opportunity to explore the latest trends learn and connect with potential partners. The past ... |
| 22.10.2024 | European funding to tackle bacterial infections and gut issues |
BioVersys continues to make progress in its clinical endeavour to develop novel antibacterial products for serious life-threatening infections caused by multi-drug resistant ("MDR") bacteria. The company has joined the EU-funded ... |
| 18.10.2024 | Positive progress in addressing unmet medical needs |
The FDA has granted Fast Track designation to Neurimmune’s partner Alexion, AstraZeneca Rare Disease Fast Track designation for the development of ALXN2220 (formerly NI006) for the treatment of transthyretin amyloidosis with cardiomyopathy... |
| 13.09.2024 | BioVersys Takes Aim at Antibiotic Resistance with New Investment and Clinical Trials in China | In the battle against antibiotic resistance, BioVersys is stepping up its game. The clinical-stage biopharmaceutical company has secured a significant investment of USD 6 million from the Guangzhou Sino-Israel Bio-Industry Investment Fund (... |
| 12.09.2024 | Bioversys secures USD 6 million investment to advance clinical program in China | BioVersys is a clinical-stage biopharmaceutical company developing novel antibacterial products to treat life-threatening infections caused by multi-drug resistant (MDR) bacteria. Their lead program, BV100, targets carbapenem-resistant Acin... |
| 11.09.2024 | Bioversys secures USD 6 million and launches clinical program in China |
BioVersys is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteri... |
| 06.06.2024 | European consortiums with Swiss startups awarded grants |
Scandens, software provider for building energy renovations, has been appointed as technology partner for EU co-funded MESTRI-CE project. With a total budget of 2.5 million Euro, the 2-year initiative aims to translate EU guidelines into a... |
| 31.05.2024 | Swiss life science startups headed for San Diego |
The BIO International Convention 2024, taking place in San Diego from 3 to 6 June, is the largest global biotechnology event with over 20,000 industry leaders from around the world attending. The target group includes representatives from ... |
| 22.05.2024 | "EMBRACING INTERNATIONAL ALLIANCES" SWISS BIOTECH INNOVATION ON DISPLAY AT THE BIO 2024 INTERNATIONAL CONVENTION IN SAN DIEGO JUNE 3-6, 2024 | ZURICH, May 22, 2024 /PRNewswire/ -- Swiss life science innovation will again be on display at the BIO 2024 convention in San Diego. Switzerland Global Enterprise will present 41 leading Swiss biotech stars at the SWISS BIOTECH pavilion dem... |
| 07.05.2024 | BioVersys and GSK Join Forces to Fight Tuberculosis | BioVersys and GSK team up to tackle tuberculosis with innovative drug development, securing additional funding to push the boundaries of treatment options for patients in need.
In a world where tuberculosis continues to pose a serious threa... |
| 07.05.2024 | BioVersys strengthens tuberculosis drug development with expanded GSK collaboration and CHF 12.3 million Series C boost | BioVersys strengthens tuberculosis drug development with expanded GSK collaboration and CHF 12.3 million Series C boost 07.05.2024 07:01, Rita Longobardi linkedIn facebook twitter instagram youtube -->
BioVersys, a clinical-stage company... |
| 07.05.2024 | BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million | - |
| 07.05.2024 | GSK joins BioVersys’ investors in series C extension round |
BioVersys is a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant ("MDR") bacteria. It... |
| 07.05.2024 | BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million | Strategic collaboration with GSK expanded to accelerate clinical development of alpibectir for the treatment of tuberculosis GSK to participate in Series C Extension with equity investment
Series C financing round extended overall by CHF 12... |
| 07.05.2024 | BioVersys strengthens tuberculosis drug development with expanded GSK collaboration and CHF 12.3 million Series C boost | "Venture Kick was really kicking BioVersys out of the comfort zone
and into full start mode. Funny anecdote: During one of the kickers camps was
my first outreach to our now long-term partner GSK...
...talking impact of Venture Kick!&q... |
| 26.01.2024 | New milestones for life sciences startups |
BioVersys AG is a clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of therapies for life-threatening multidrug-resistant bacterial infections and targeted microbiome modulation. The company is d... |
| 12.12.2023 | FDA grants BioVersys orphan-drug designation | |
| 09.11.2023 | Newly appointed executives to make startups top notch | |
| 10.05.2023 | Biotech startups turn gear into Phase 2 clinical trials | |
| 28.04.2023 | Swiss Accelerator: Innosuisse supports 53 companies with CHF112 million | |
| 06.01.2023 | BioVersys Extends its Series C Round to CHF 32.6M | BioVersys, a Basel, Switzerland-based privately held clinical stage, multi-asset pharmaceutical company, extended its Series C funding to CHF 32.6M.
The round was led by AMR Action Fund. Carly Levine, PhD, of the AMR Action Fund will join B... |
| 05.01.2023 | BioVersys raises CHF 32.6 million in extended Series C round | BioVersys AG is a privately held clinical-stage, multi-asset Swiss pharmaceutical company focusing on the research and development of therapies for life-threatening multidrug-resistant bacterial infections and targeted microbiome modulation... |
| 05.01.2023 | BioVersys raises CHF 32.6 million in extended Series C round | BioVersys raises CHF 32.6 million in extended Series C round 05.01.2023 13:15, Morgane Ghilardi linkedIn facebook twitter instagram youtube -->
BioVersys announced the extension of its Series C investment round, reaching a total of CHF 3... |
| 05.01.2023 | BioVersys secures an additional CHF 8.4 million to advance clinical studies | |
| 20.09.2022 | Applauses for Swiss Innovators | |
| 21.06.2022 | Second successful Phase I trial for BioVersys | |
| 08.06.2022 | BioVersys closes a CHF 24.2 million financing round to develop AMR medical pipeline | The confidence of their investors and the renewed interest of established pharma and biotech companies in AMR validate the importance of the sector and the value of Bioversys' portfolio of de-risked assets. In 2019, 1.27 million deaths were... |
| 08.06.2022 | BioVersys closes a CHF 24.2 million financing round to develop AMR medical pipeline | BioVersys closes a CHF 24.2 million financing round to develop AMR medical pipeline 08.06.2022 09:00, Guillaume Tinsel linkedIn facebook twitter instagram youtube -->
BioVersys AG, a privately-held clinical-stage, multi-asset Swiss pharm... |
| 08.06.2022 | BioVersys attracts CHF 24.2 million to develop clinical pipeline | |
| 02.06.2022 | Sparks IPO Academy completes first edition with 13 companies | |
| 03.05.2022 | BioVersys' BV100 advances into phase II clinical trials | |
| 01.06.2021 | BioVersys gets up to USD 15.34 million CARB-X grant to further develop pyrrolocytosines, a novel class of broad-spectrum antibiotics | BioVersys gets up to USD 15.34 million CARB-X grant to further develop pyrrolocytosines, a novel class of broad-spectrum antibiotics 01.06.2021 09:00, Guillaume Tinsel linkedIn facebook twitter instagram youtube -->
TOP 100 Swiss Startup... |
| 01.06.2021 | BioVersys gets up to USD 15.34 million CARB-X grant to further develop pyrrolocytosines, a novel class of broad-spectrum antibiotics | BioVersys AG, a privately owned clinical-stage, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for multidrug-resistant bacterial infections with applications in antimicrobial resistance (AMR... |
| 01.06.2021 | BioVersys secures additional funding | |
| 01.06.2021 | BioVersys secures additional funding | BioVersys AG is a multi-asset Swiss pharmaceutical company focusing on developing small molecules for multidrug-resistant bacterial infections with applications in antimicrobial resistance (AMR) and targeted microbiome modulation. The compa... |
| 15.04.2021 | BioVersys receives €20 million in EU financing to develop new antibiotics | |
| 15.04.2021 | BioVersys receives €20 million in EU financing to develop new antibiotics | BioVersys AG is a clinical-stage pharmaceutical company developing treatments for multidrug-resistant bacterial infections for which there is a major medical need. Some 700 000 people die each year due to drug-resistant diseases, and accord... |
| 14.04.2021 | BioVersys receives EUR 20 million in EU financing to support the development of new antibiotics | BioVersys receives EUR 20 million in EU financing to support the development of new antibiotics 14.04.2021 09:00, Isabelle Mitchell linkedIn facebook twitter instagram youtube -->
The European Investment Bank and BioVersys sign a financi... |
| 14.04.2021 | BioVersys receives EUR 20 million in EU financing to support the development of new antibiotics | The European Investment Bank (EIB) and BioVersys AG, a clinical-stage pharmaceutical company developing treatments for multidrug-resistant bacterial infections, signed a EUR 20 million venture debt transaction. The financing supports the co... |
| 24.02.2021 | BioVersys and consortium partners obtain €2.7 million grant | BioVersys AG is a privately owned, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for multidrug-resistant bacterial infections with applications in Anti-Microbial Resistance (AMR) and target... |
| 24.02.2021 | BioVersys and consortium partners obtain €2.7 million grant | |
| 13.01.2021 | BioVersys’ second drug candidate enters clinical trials | BioVersys AG develops small molecules for multidrug-resistant bacterial infections. Having brought its first drug candidate BV100 into clinical trials last year in November, the company has kicked off another clinical phase of its second pr... |
| 13.01.2021 | BioVersys’ second drug candidate enters clinical trials | |
| 08.01.2021 | BAS members invested a 7-digit amount in start-ups in 2020 | Business Angels Switzerland is an association comprising private individuals that are willing to invest time and money in small, newly founded companies with innovative projects. The club consists of approximately 100 members split over two... |
| 08.01.2021 | BAS members invested a 7-digit amount in start-ups in 2020 | Normal 0 false false false DE-CH X-NONE X-NONE |
| 19.11.2020 | BioVersys doses first subjects in Phase 1 clinical trial of BV100 | BioVersys is a privately owned, multi-asset Swiss pharmaceutical company focused on developing small molecules for multidrug-resistant bacterial infections with applications in Anti-Microbial Resistance (AMR) and targeted microbiome modulat... |
| 19.11.2020 | BioVersys doses first subjects in Phase 1 clinical trial of BV100 | |
| 01.09.2020 | BioVersys Raises CHF 19M in Funding | BioVersys, a Basel, Switzerland-based pharmaceutical company, closed a CHF 19m Series B financing round.
The company intends to use the funds – which complement the CHF 16.5m of non-dilutive funding raised in 2019 from CARB-X and the IMI2-J... |
| 01.09.2020 | BioVersys announces CHF 19 million financing round to advance novel AMR candidates into clinical development | BioVersys was founded in 2008 and was a Venture Kick winner in the same year, a Venture Leader in 2008 and 2016, and one of the TOP 100 Swiss startups for three consecutive years (2011-2013). The privately owned, multi-asset Swiss pharmaceu... |
| 01.09.2020 | A CHF 19 Million round brings BioVersys closer to clinical Phase 1 | BioVersys is a privately owned, multi-asset Swiss pharmaceutical company focusing on the development of small molecules for multidrug-resistant bacterial infections with applications in Anti-Microbial Resistance (AMR) and targeted microbiom... |
| 01.09.2020 | A CHF 19 Million round brings BioVersys closer to clinical Phase 1 | |
| 01.09.2020 | BioVersys announces CHF 19 million financing round to advance novel AMR candidates into clinical development | BioVersys announces CHF 19 million financing round to advance novel AMR candidates into clinical development 01.09.2020 09:00, Isabelle Mitchell linkedIn facebook twitter instagram youtube -->
BioVersys completed a CHF 19 million Series ... |
| 23.06.2020 | BioVersys prepares first in-human trials for anti-tuberculosis treatment | Based in Basel, BioVersys is a privately owned, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for multidrug-resistant bacterial infections. The clinical candidate BVL-GSK098 originates from... |
| 23.06.2020 | BioVersys prepares first in-human trials for anti-tuberculosis treatment | |
| 24.01.2020 | Venture Kick to inject 5 million Swiss francs in 80 projects | |
| 24.01.2020 | Venture Kick to inject 5 million Swiss francs in 80 projects | Venture Kick is a philanthropic initiative that provides up to CHF 150,000 in seed funding to Swiss startups in addition to a well-structured entrepreneurial path towards building a winning business. Startups pitch to expert juries at three... |
| 19.12.2019 | Global accolades for Swiss innovations | |
| 29.10.2019 | BioVersys obtains new funds for its fight against drug-resistant bacteria | |
| 24.10.2019 | Four Swiss startups to explore China | |
| 20.06.2019 | BioVersys receives a grant of €7 million | |
| 27.05.2019 | The FDA grants BioVersys preferential treatment | |
| 27.11.2018 | Schweizer Startups holen sich erfahrene Manager ins Boot | |
| 10.08.2018 | BioVersys s’implante à Lille pour intensifier la recherche et le développement | |
| 22.11.2017 | BioVersys AG raises CHF5 million in Series A2 round | |
| 08.03.2017 | Bioversys and Aptuit team up to fight antibiotic resistance | |
| 04.10.2016 | #vleaders China 2016: Meet Marc Gitzinger of BioVersys | #vleaders China 2016: Meet Marc Gitzinger of BioVersys 04.10.2016 10:00, Lara Rossi linkedIn facebook twitter instagram youtube -->
From October 24 to November 3, 2016, 10 great Swiss startups will go international with the venture leade... |
| 04.10.2016 | #vleaders China 2016: Meet Marc Gitzinger of BioVersys | Meet Marc Gitzinger, CEO of BioVersys
BioVersys focuses on research and development of small molecules, which switch off drug resistance against existing antibiotics. The Swiss biopharmaceutical company addresses the high unmet medical need... |
| 24.08.2016 | Ten new Swiss startups selected to conquer China and its investors in 2016 | For Swiss startups, China is a key market to explore. With the necessity to increase the visibility of Swiss high-tech innovation in China, venturelab launched the first edition of venture leaders China in 2014 on the model of the venture l... |
| 24.08.2016 | Ten new Swiss startups selected to conquer China | |
| 24.08.2016 | Ten new Swiss startups selected to conquer China and its investors in 2016 | Ten new Swiss startups selected to conquer China and its investors in 2016 24.08.2016 14:00, Lara Rossi linkedIn facebook twitter instagram youtube -->
After a very successful second edition of the program venture leaders China in 2015, ... |
| 11.02.2016 | Anmeldung für den Jungunternehmerpreis Nordwestschweiz 2016 ist eröffnet | |
| 18.12.2014 | BioVersys is the first to achieve the seif Label | |
| 08.12.2014 | BioVersys achieves first milestone in project to fight tuberculosis | BioVersys, 2008 venture kick winner and venture leader USA, announced together with the University of Lille that they had reached the first milestone in their collaboration with GlaxoSmithKline (GSK). The collaboration, which started in May... |
| 08.12.2014 | BioVersys achieves first milestone in project to fight tuberculosis | BioVersys achieves first milestone in project to fight tuberculosis 08.12.2014 17:00, Lara Rossi linkedIn facebook twitter instagram youtube -->
9 December 2014 - In May this year, BioVersys started a project in collaboration with Lille ... |
| 04.12.2014 | BioVersys and Université de Lille achieve first milestone in collaboration with GlaxoSmithKline | |
